Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Preferred Stock Liabilities of $239.4 million in Q4 2021, up 271.74% quarter-over-quarter from $64.4 million in Q3 2021.
Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021) Analysis & Trends
Amylyx Pharmaceuticals' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $239.4 million for Q4 2021.
- In Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $239.4 million; the TTM figure through Dec 2021 stood at $239.4 million (changed N/A YoY), while the FY2021 annual figure was $239.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $239.4 million for Q4 2021 at Amylyx Pharmaceuticals, up from $64.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $239.4 million in Q4 2021 to a low of $7.7 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 239.35 Mn |
| Sep 30, 2021 | 64.39 Mn |
| Jun 30, 2021 | 64.39 Mn |
| Mar 31, 2021 | 7.68 Mn |